TC BioPharm's boasts a strong IP portfolio of patents covering manufacturing and commercialization of GD-T cell products and their modification via CAR-T. Currently The Company owns 6 granted patents and a further 45 patent applications in 6 families encompassing: allogeneic gamma-delta T cells; novel 'co-stimulatory' gamma-delta CAR-T cells intended to mitigate on-target, off-tumour toxicity and broaden the choice of therapeutic targets addressable by CAR-T therapies; novel CAR constructs tailored for use in gamma-delta T-cells; modified gamma-delta T-cells intended to maintain activity in the immune suppressive solid tumour microenvironment; and proprietary antigen binders,and have an exclusive license to an additional 1 family of 3 granted patent application and 11 patent applications in the area of 'co-stimulatory' gamma-delta CAR-T cells.
Market Data 
Markets 
AI
